Azeliragon ameliorates Alzheimer's disease via the Janus tyrosine kinase and signal transducer and activator of transcription signaling pathway

OBJECTIVES: TTP488, an antagonist of the receptor for advanced glycation end-products, was evaluated as a potential treatment for patients with mild-to-moderate Alzheimer’s disease (AD). However, the mechanism underlying the protective action of TTP488 against AD has not yet been fully explored. MET...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Lijuan, Liu, Yepei, Wang, Yuanyuan, Li, Junsheng, Liu, Na
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Faculdade de Medicina / USP 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920406/
https://www.ncbi.nlm.nih.gov/pubmed/33681944
http://dx.doi.org/10.6061/clinics/2021/e2348

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920406/
https://www.ncbi.nlm.nih.gov/pubmed/33681944
http://dx.doi.org/10.6061/clinics/2021/e2348

Ejemplares similares